» Articles » PMID: 33447639

Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study

Abstract

Background: Bacterial infections may complicate viral pneumonias. Recent reports suggest that bacterial co-infection at time of presentation is uncommon in coronavirus disease 2019 (COVID-19); however, estimates were based on microbiology tests alone. We sought to develop and apply consensus definitions, incorporating clinical criteria to better understand the rate of co-infections and antibiotic use in COVID-19.

Methods: A total of 1016 adult patients admitted to 5 hospitals in the Johns Hopkins Health System between March 1, 2020, and May 31, 2020, with COVID-19 were evaluated. Adjudication of co-infection using definitions developed by a multidisciplinary team for this study was performed. Both respiratory and common nonrespiratory co-infections were assessed. The definition of bacterial community-acquired pneumonia (bCAP) included proven (clinical, laboratory, and radiographic criteria plus microbiologic diagnosis), probable (clinical, laboratory, and radiographic criteria without microbiologic diagnosis), and possible (not all clinical, laboratory, and radiographic criteria met) categories. Clinical characteristics and antimicrobial use were assessed in the context of the consensus definitions.

Results: Bacterial respiratory co-infections were infrequent (1.2%); 1 patient had proven bCAP, and 11 (1.1%) had probable bCAP. Two patients (0.2%) had viral respiratory co-infections. Although 69% of patients received antibiotics for pneumonia, the majority were stopped within 48 hours in patients with possible or no evidence of bCAP. The most common nonrespiratory infection was urinary tract infection (present in 3% of the cohort).

Conclusions: Using multidisciplinary consensus definitions, proven or probable bCAP was uncommon in adults hospitalized due to COVID-19, as were other nonrespiratory bacterial infections. Empiric antibiotic use was high, highlighting the need to enhance antibiotic stewardship in the treatment of viral pneumonias.

Citing Articles

Antimicrobial use before and during COVID-19: data from 108 Veterans Affairs medical centers.

Goetz M, Willson T, Rubin M, Stevens V, Graber C Antimicrob Steward Healthc Epidemiol. 2025; 4(1):e109.

PMID: 39823121 PMC: 11736461. DOI: 10.1017/ash.2024.352.


Levees for a hundred-year flood: impact of a syndrome-based antimicrobial stewardship intervention for coronavirus disease 2019 on antimicrobial use and resistance.

Mena Lora A, Burgos R, Huber D, Sanchez L, Ali M, Krill C Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e131.

PMID: 39346665 PMC: 11427971. DOI: 10.1017/ash.2024.383.


Use of RT-PCR in conjunction with a respiratory pathogen assay to concurrently determine the prevalence of bacteria and SARS-CoV-2 from the nasopharynx of outpatients.

Shurko J, Page R, Mares C, Nguyen V, Lopez K, Vanee N Front Epidemiol. 2024; 3:1274800.

PMID: 38455907 PMC: 10910948. DOI: 10.3389/fepid.2023.1274800.


Antibiotic Use Among Hospitalized Patients With COVID-19 in the United States, March 2020-June 2022.

Kim C, Wolford H, Baggs J, Reddy S, Hicks L, Neuhauser M Open Forum Infect Dis. 2023; 10(11):ofad503.

PMID: 37942462 PMC: 10629359. DOI: 10.1093/ofid/ofad503.


Characterization of respiratory bacterial co-infection and assessment of empirical antibiotic treatment in patients with COVID-19 at hospital admission.

Antuori A, Gimenez M, Linares G, Cardona P Sci Rep. 2023; 13(1):19302.

PMID: 37935785 PMC: 10630415. DOI: 10.1038/s41598-023-46692-x.


References
1.
Vaughn V, Gandhi T, Petty L, Patel P, Prescott H, Malani A . Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study. Clin Infect Dis. 2020; 72(10):e533-e541. PMC: 7499526. DOI: 10.1093/cid/ciaa1239. View

2.
Alanio A, Delliere S, Fodil S, Bretagne S, Megarbane B . Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020; 8(6):e48-e49. PMC: 7239617. DOI: 10.1016/S2213-2600(20)30237-X. View

3.
Joseph C, Togawa Y, Shindo N . Bacterial and viral infections associated with influenza. Influenza Other Respir Viruses. 2013; 7 Suppl 2:105-113. PMC: 5909385. DOI: 10.1111/irv.12089. View

4.
McLaughlin J, Jiang Q, Isturiz R, Sings H, Swerdlow D, Gessner B . Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin Infect Dis. 2018; 67(10):1498-1506. PMC: 6206101. DOI: 10.1093/cid/ciy312. View

5.
Metlay J, Waterer G, Long A, Anzueto A, Brozek J, Crothers K . Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200(7):e45-e67. PMC: 6812437. DOI: 10.1164/rccm.201908-1581ST. View